Middle East and Africa antiviral drugs market is expected to reach USD 2,225.82 million by 2030 from USD 1,771.23 million in 2022, growing with a CAGR of 2.9% during the forecast period from 2023 to 2030. Market Segmentation: Middle East and Africa Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030. Overview of Middle East and Africa Antiviral Drugs Market Dynamics : Driver • Rising prevalence of viral infections Restrain • High cost of antiviral drugs Opportunity • Increasing collaboration and partnership among key players Market Players: Some of the key market players operating in the Middle East and Africa antiviral drugs market are listed below: • Gilead Sciences, Inc. • F. Hoffmann-La Roche Ltd • GLAXOSMITHKLINE PLC • Abbvie • Merck & Co., Inc. • Johnson & Johnson Services, Inc. • Bristol-Myers Squibb Company • Cipla Inc. • Aurobindo Pharma • Dr. Reddy’s Laboratories Ltd. • Zydus Pharmaceuticals, Inc. • Mylan Pharmaceuticals ULC • Teva Pharmaceuticals USA, Inc. • EMERGENT • Sun Pharmaceutical Industries Ltd. • Avet Pharmaceuticals Inc. • Pfizer Inc. • SIGA Technologies • NAVINTA LLC. • Macleods Pharmaceuticals Ltd. • BioCryst Pharmaceuticals, Inc • Hetero

1 INTRODUCTION 119 1.1 OBJECTIVES OF THE STUDY 119 1.2 MARKET DEFINITION 119 1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET 119 1.4 LIMITATIONS 121 1.5 MARKETS COVERED 121 2 MARKET SEGMENTATION 127 2.1 MARKETS COVERED 127 2.2 GEOGRAPHICAL SCOPE 128 2.3 YEARS CONSIDERED FOR THE STUDY 129 2.4 CURRENCY AND PRICING 129 2.5 DBMR TRIPOD DATA VALIDATION MODEL 130 2.6 MULTIVARIATE MODELLING 133 2.7 PRODUCT TYPE LIFELINE CURVE 133 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134 2.9 DBMR MARKET POSITION GRID 135 2.10 MARKET TESTING TYPE COVERAGE GRID 136 2.11 VENDOR SHARE ANALYSIS 137 2.12 SECONDARY SOURCES 138 2.13 ASSUMPTIONS 138 3 EXECUTIVE SUMMARY 139 4 PREMIUM INSIGHTS 142 4.1 PORTER’S FIVE FORCES 143 4.2 PESTEL ANALYSIS 144 5 EPIDEMIOLOGY 145 6 PIPELINE ANALYSIS FOR MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET 146 7 REGULATORY FRAMEWORK 147 8 MARKET OVERVIEW 149 8.1 DRIVERS 151 8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 151 8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 151 8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 153 8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 153 8.2 RESTRAINS 154 8.2.1 HIGH COST OF ANTIVIRAL DRUGS 154 8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 154 8.3 OPPORTUNITIES 155 8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 155 8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 155 8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 156 8.4 CHALLENGES 157 8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 157 8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 158 9 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION 159 9.1 OVERVIEW 160 9.2 INFLUENZA 163 9.2.1 NEURAMINIDASE INHIBITORS 164 9.2.1.1 OSELTAMIVIR 164 9.2.1.2 ZANAMIVIR 164 9.2.1.3 PERAMIVIR 164 9.2.1.4 LANINAMIVIR 164 9.2.2 M2 INHIBITORS 165 9.2.2.1 RIMANTADINE 165 9.2.2.2 OTHERS 165 9.2.3 RNA POLYMERASE INHIBITORS 165 9.2.3.1 FAVIPIRAVIR 165 9.2.3.2 BALOXAVIR MARBOXIL 165 9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 166 9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 167 9.3.1.1 NUCLEOSIDE (NRTIS) 167 9.3.1.1.1 LAMIVUDINE 168 9.3.1.1.2 ABACAVIR 168 9.3.1.1.3 DIDANOSINE 168 9.3.1.1.4 OTHERS 168 9.3.1.2 NONNUCLEOSIDE (NNRTIS) 168 9.3.1.2.1 EFAVIRENZ 168 9.3.1.2.2 NEVIRAPINE 168 9.3.1.2.3 DELAVIRDINE 168 9.3.1.2.4 OTHERS 169 9.3.1.3 INTEGRASE 169 9.3.1.3.1 DOLUTEGRAVIR 169 9.3.1.3.2 ELVITEGRAVIR 169 9.3.1.3.3 RALTEGRAVIR 169 9.3.1.3.4 BICTEGRAVIR 169 9.3.1.4 NUCLEOTIDE 169 9.3.1.4.1 TENOFOVIR 170 9.3.1.4.2 OTHERS 170 9.3.1.5 INTERFERONS 170 9.3.1.5.1 ALPHA 170 9.3.1.5.2 BETA 170 9.3.1.5.3 GAMMA 171 9.3.1.6 GP41 171 9.3.1.6.1 ENFUVIRTIDE 171 9.3.1.6.2 OTHERS 171 9.3.2 PROTEASE 172 9.3.2.1 ATAZANAVIR 172 9.3.2.2 DARUNAVIR 172 9.3.2.3 LOPINAVIR 172 9.3.2.4 RITONAVIR 172 9.3.2.5 SAQUINAVIR 172 9.3.2.6 INDINAVIR 172 9.3.2.7 NELFINAVIR 173 9.3.2.8 TIPRANAVIR 173 9.3.2.9 AMPRENAVIR 173 9.4 HEPATITIS C VIRUS 173 9.4.1 NS5B POLYMERASE 174 9.4.1.1 SOFOSBUVIR 174 9.4.1.2 DASABUVIR 174 9.4.2 NS3/4A PROTEASE 175 9.4.2.1 DANOPREVIR 175 9.4.2.2 GLECAPREVIR 175 9.4.2.3 GRAZOPREVIR 175 9.4.2.4 PARITAPREVIR 175 9.4.2.5 SIMEPREVIR 175 9.4.3 NS5A PHOSPHOPROTEIN 176 9.4.3.1 LEDIPASVIR 176 9.4.3.2 VELPATASVIR 176 9.4.3.3 OMBITASVIR 176 9.4.3.4 ELBASVIR 176 9.4.3.5 DACLATASVIR 176 9.4.3.6 PIBRENTASVIR 176 9.4.4 NEURAMINIDASE 177 9.4.4.1 OSELTAMIVIR 177 9.4.4.2 ZANAMIVIR 177 9.4.4.3 PERAMIVIR 177 9.4.4.4 LANINAMIVIR 177 9.4.5 RNA POLYMERASE 177 9.4.5.1 BALOXAVIR MARBOXIL 178 9.4.5.2 FAVIPIRAVIR 178 9.4.6 MATRIX PROTEIN 2 178 9.4.6.1 RIMATIDINE 178 9.4.6.2 FAVIPIRAVIR 178 9.5 HERPES SIMPLEX VIRUS 179 9.5.1 DNA POLYMERASE UL30 180 9.5.1.1 ACICLOVIR 180 9.5.1.2 FAMCICLOVIR 180 9.5.1.3 VALACICLOVIR 180 9.5.1.4 PENCICLOVIR TRIFLURIDINE 180 9.5.1.5 BRIVUDINE 180 9.5.1.6 FOSCARNET 180 9.5.1.7 IDOXURIDINE 181 9.5.2 ENVELOPE PROTEINS 181 9.5.2.1 DOCOSANOL 181 9.5.2.2 OTHERS 181 9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 181 9.6.1 GANCICLOVIR 182 9.6.2 VALGANCICLOVIR 182 9.6.3 CIDOFOVIR 182 9.6.4 FOSCARNET 182 9.6.5 FOMIVIRSEN 182 9.7 VARICELLA-ZOSTER VIRUS (VZV) 183 9.7.1 VALACICLOVIR 184 9.7.2 FAMCICLOVIR 184 9.7.3 ACICLOVIR 184 9.7.4 VIDARABINE 184 9.7.5 BRIVUDINE 184 9.8 HEPATITIS B VIRUS 184 9.8.1 ENTECAVIR 185 9.8.2 TENOFOVIR 185 9.8.3 TELBIVUDINE 185 9.8.4 TENOFOVIR ALAFENAMIDE 186 9.8.5 OTHERS 186 9.9 RESPIRATORY SYNCYTIAL VIRUS 186 9.9.1 RNA POLYMERASE 187 9.9.1.1 RIBAVIRIN 187 9.9.1.2 OTHERS 187 9.9.2 FUSION GLYCOPROTEIN 187 9.9.2.1 PALIVIZUMAB 188 9.9.2.2 OTHERS 188 9.10 CORONAVIRUS INFECTION 188 9.11 OTHERS 189 10 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 190 10.1 OVERVIEW 191 10.2 GERIATRIC 194 10.2.1 MALE 194 10.2.2 FEMALE 194 10.3 CHILD 195 10.3.1 MALE 195 10.3.2 FEMALE 196 10.4 ADULT 196 10.4.1 MALE 197 10.4.2 FEMALE 197 11 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS 198 11.1 OVERVIEW 199 11.2 ORAL 202 11.2.1 SOLID 203 11.2.1.1 TABLETS 203 11.2.1.2 CAPSULES 203 11.2.1.3 OTHERS 203 11.2.2 SEMISOLID 203 11.2.2.1 GELS 204 11.2.2.2 EMULSIONS 204 11.2.2.3 ELIXIRS 204 11.2.2.4 OTHERS 204 11.2.3 LIQUID 204 11.2.3.1 SOLUTIONS 204 11.2.3.2 SYRUPS 204 11.2.3.3 OTHERS 204 11.3 TOPICAL 205 11.3.1 SEMI-SOLID 206 11.3.1.1 CREAM 206 11.3.1.2 OINTMENT 206 11.3.1.3 GELS 206 11.3.1.4 OTHERS 206 11.3.2 LIQUID 206 11.3.2.1 SOLUTIONS 207 11.3.2.2 SUSPENSIONS 207 11.3.3 SOLID 207 11.3.3.1 POWDERS 207 11.3.3.2 SUPPOSITORIES 207 11.3.3.3 ENEMA 207 11.3.3.4 OTHERS 207 11.4 PARENTERAL 208 11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 209 11.4.1.1 SOLUTIONS 209 11.4.1.2 RECONSTITUTED/LYOPHILIZED 209 11.4.1.3 SUSPENSIONS 209 11.4.1.4 EMULSIONS 209 11.4.1.5 OTHERS 209 11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 210 11.4.3 COLLOIDAL DISPERSIONS 210 11.4.4 LONG ACTING INJECTION FORMULATION 210 12 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 211 12.1 OVERVIEW 212 12.2 GENERIC 215 12.3 BRANDED 215 13 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER 216 13.1 OVERVIEW 217 13.2 HOSPITAL 220 13.3 SPECIALTY CENTERS 220 13.4 AMBULATORY CENTRES 221 13.5 CLINICS 221 13.6 HOME HEALTHCARE 221 13.7 OTHERS 222 14 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 223 14.1 OVERVIEW 224 14.2 HOSPITAL PHARMACY 227 14.3 RETAIL PHARMACY 227 14.4 ONLINE PHARMACY 228 15 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY REGION 229 15.1 MIDDLE EAST AND AFRICA 230 15.1.1 SOUTH AFRICA 249 15.1.2 SAUDI ARABIA 263 15.1.3 UAE 277 15.1.4 EGYPT 291 15.1.5 KUWAIT 305 15.1.6 ISRAEL 319 15.1.7 REST OF MIDDLE EAST AND AFRICA 333 16 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 334 16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 334 17 SWOT ANALYSIS 335 18 COMPANY PROFILE 336 18.1 GILEAD SCIENCES, INC. (2022) 336 18.1.1 COMPANY SNAPSHOT 336 18.1.2 REVENUE ANALYSIS 336 18.1.3 COMPANY SHARE ANALYSIS 337 18.1.4 PRODUCT PORTFOLIO 337 18.1.5 RECENT DEVELOPMENT 337 18.2 PFIZER INC. (2022) 338 18.2.1 COMPANY SNAPSHOT 338 18.2.2 REVENUE ANALYSIS 338 18.2.3 COMPANY SHARE ANALYSIS 339 18.2.4 PRODUCT PORTFOLIO 339 18.2.5 RECENT DEVELOPMENTS 339 18.3 SIGA TECHNOLOGIES (2022) 340 18.3.1 COMPANY SNAPSHOT 340 18.3.2 REVENUE ANALYSIS 340 18.3.3 COMPANY SHARE ANALYSIS 341 18.3.4 PRODUCT PORTFOLIO 341 18.3.5 RECENT DEVELOPMENT 341 18.4 GLAXOSMITHKLINE PLC 342 18.4.1 COMPANY SNAPSHOT 342 18.4.2 REVENUE ANALYSIS 342 18.4.3 COMPANY SHARE ANALYSIS 343 18.4.4 PRODUCT PORTFOLIO 343 18.4.5 RECENT DEVELOPMENT 343 18.5 F. HOFFMANN-LA ROCHE LTD. (2022) 344 18.5.1 COMPANY SNAPSHOT 344 18.5.2 REVENUE ANALYSIS 344 18.5.3 COMPANY SHARE ANALYSIS 345 18.5.4 PRODUCT PORTFOLIO 345 18.5.5 RECENT DEVELOPMENT 345 18.6 ABBVIE INC 346 18.6.1 COMPANY SNAPSHOT 346 18.6.2 REVENUE ANALYSIS 346 18.6.3 PRODUCT PORTFOLIO 347 18.6.4 RECENT DEVELOPMENT 347 18.7 AUROBINDO PHARMA (2022) 348 18.7.1 COMPANY SNAPSHOT 348 18.7.2 REVENUE ANALYSIS 348 18.7.3 PRODUCT PORTFOLIO 349 18.7.4 RECENT DEVELOPMENT 349 18.8 AVET PHARMACEUTICALS INC 350 18.8.1 COMPANY SNAPSHOT 350 18.8.2 PRODUCT PORTFOLIO 350 18.8.3 RECENT DEVELOPMENT 350 18.9 BRISTOLL MYERS SQUIBB (2022) 351 18.9.1 COMPANY SNAPSHOT 351 18.9.2 REVENUE ANALYSIS 351 18.9.3 PRODUCT PORTFOLIO 352 18.9.4 RECENT DEVELOPMENT 352 18.10 BIOCRYST PHARMACEUTICALS, INC. (2022) 353 18.10.1 COMPANY SNAPSHOT 353 18.10.2 REVENUE ANALYSIS 353 18.10.3 PRODUCT PORTFOLIO 354 18.10.4 RECENT DEVELOPMENT 354 18.11 CIPLA INC. (2022) 355 18.11.1 COMPANY SNAPSHOT 355 18.11.2 REVENUE ANALYSIS 355 18.11.3 PRODUCT PORTFOLIO 356 18.11.4 RECENT DEVELOPMENT 356 18.12 DR. REDDY’S LABORATORIES LTD. (2022) 357 18.12.1 COMPANY SNAPSHOT 357 18.12.2 REVENUE ANALYSIS 357 18.12.3 PRODUCT PORTFOLIO 358 18.12.4 RECENT DEVELOPMENTS 358 18.13 EMERGENT (2022) 359 18.13.1 COMPANY SNAPSHOT 359 18.13.2 REVENUE ANALYSIS 359 18.13.3 PRODUCT PORTFOLIO 360 18.13.4 RECENT DEVELOPMENT 360 18.14 HETERO 361 18.14.1 COMPANY SNAPSHOT 361 18.14.2 PRODUCT PORTFOLIO 361 18.14.3 RECENT DEVELOPMENT 361 18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022) 362 18.15.1 COMPANY SNAPSHOT 362 18.15.2 REVENUE ANALYSIS 362 18.15.3 PRODUCT PORTFOLIO 363 18.15.4 RECENT DEVELOPMENT 363 18.16 MACLEODS PHARMACEUTICALS LTD 364 18.16.1 COMPANY SNAPSHOT 364 18.16.2 PRODUCT PORTFOLIO 364 18.16.3 RECENT DEVELOPMENT 364 18.17 MERCK & CO., INC, (2022) 365 18.17.1 COMPANY SNAPSHOT 365 18.17.2 REVENUE ANALYSIS 365 18.17.3 PRODUCT PORTFOLIO 366 18.17.4 RECENT DEVELOPMENT 366 18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022) 367 18.18.1 COMPANY SNAPSHOT 367 18.18.2 REVENUE ANALYSIS 367 18.18.3 PRODUCT PORTFOLIO 368 18.18.4 RECENT DEVELOPMENT 368 18.19 NAVINTA LLC 369 18.19.1 COMPANY SNAPSHOT 369 18.19.2 PRODUCT PORTFOLIO 369 18.19.3 RECENT DEVELOPMENT 369 18.20 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022) 370 18.20.1 COMPANY SNAPSHOT 370 18.20.2 REVENUE ANALYSIS 370 18.20.3 PRODUCT PORTFOLIO 371 18.20.4 RECENT DEVELOPMENT 371 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022) 372 18.21.1 COMPANY SNAPSHOT 372 18.21.2 REVENUE ANALYSIS 372 18.21.3 PRODUCT PORTFOLIO 373 18.21.4 RECENT DEVELOPMENT 373 18.22 ZYDUS PHARMACEUTICALS, INC. (2022) 374 18.22.1 COMPANY SNAPSHOT 374 18.22.2 REVENUE ANALYSIS 374 18.22.3 PRODUCT PORTFOLIO 375 18.22.4 RECENT DEVELOPMENTS 375 19 QUESTIONNAIRE 376 20 RELATED REPORTS 379